Skip to content

Terms of Use

Content is informational. Affiliate links may earn commission. Tirzepatidetablets is not affiliated with any vendor unless explicitly stated.

Reviewed by the Tirzepatidetablets Research Team · Last updated January 2026

References & Scientific Sources

  1. Del Prato S, et al. Tirzepatide versus insulin glargine (SURPASS-4). Lancet. 2021.
  2. Coskun T, et al. Tirzepatide, a dual GIP/GLP-1 receptor agonist: mechanism. Mol Metab. 2018.
  3. Jastreboff AM, et al. Tirzepatide once weekly for obesity (SURMOUNT-1). N Engl J Med. 2022.

Sources are provided for educational reference. This content is informational and not a substitute for professional medical advice.